Drug Trial Radar · NCT02813694
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
738
Actual
Start
Aug 2016
Primary completion
Jan 2018
Study completion Jan 2018
Sponsor
- Lead sponsor
- Nabriva Therapeutics AGIndustry
- Sponsor type
- Industry
- First posted
- Jun 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate community-acquired bacterial pneumonia
Conditions
- Community Acquired Pneumonia
Interventions
lefamulinDrug
antibacterial agent
MoxifloxacinDrug
antibacterial agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical Response (ECR)Time frame: 96 hours +/- 24 hours after first dose of study drug
Locations
155 sites in 20 countries. Site status is shown where the registry gives one.
1080
Beverly Hills, California
Site 1065
Fresno, California
1078
Northridge, California
Site 1072
Oxnard, California
Site 1070
Sacramento, California
1079
Sherman Oaks, California
Site 1053
Sylmar, California
Site 1064
DeBary, Florida
Site 1052
DeLand, Florida
1076
Miami, Florida
Site 1051
Michigan City, Indiana
Site 1057
Natchitoches, Louisiana
Site 1073
New Bedford, Massachusetts
Site 1055
Detroit, Michigan
Site 1062
Detroit, Michigan
Site 1068
Royal Oak, Michigan
Site 1058
St Louis, Missouri
Site 1054
Butte, Montana
Site 1067
Lima, Ohio
Site 1056
Rapid City, South Dakota
1077
Hendersonville, Tennessee
Site 1060
Houston, Texas
Site 1069
Houston, Texas
Site 1066
Splendora, Texas
Site 1059
Charlottesville, Virginia
Site 3056
Buenos Aires, Argentina
Site 3059
Buenos Aires AV, Argentina
Site 3054
Córdoba, Argentina
Site 3052
Córdoba, Argentina
Site 3057
Córdoba, Argentina
Site 3058
General Pacheco, Argentina
Site 3051
La Plata, Argentina
Site 3053
La Plata, Argentina
Site 3154
Belo Horizonte, Brazil
Site 3153
Passo Fundo, Brazil
Site 3152
São José do Rio Preto, Brazil
4162
Rousse, Bulgaria
Site 4154
Sliven, Bulgaria
Site 4160
Sofia, Bulgaria
Site 4157
Sofia, Bulgaria
Showing 40 of 155 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.